Literature DB >> 23266076

The prognostic implications of Hyam's subtype for patients with Kadish stage C esthesioneuroblastoma.

Gurvinder Kaur1, Ari J Kane, Michael E Sughrue, Michelle Madden, Michael C Oh, Matthew Z Sun, Michael Safaee, Ivan El-Sayed, Manish Aghi, Michael W McDermott, Mitchel S Berger, Andrew T Parsa.   

Abstract

Esthesioneuroblastoma (EN) is a rare sinonasal tumor with varied aggressiveness and potential for intracranial invasion. EN is staged anatomically with radiographic evaluation using the Kadish staging system (stages A, B, and C) and histologically by using Hyam's criteria (grades 1-4). Here we show that despite radiographic evidence of aggressive features, the prognosis of patients with Kadish stage C EN is best predicted by tumor histology using Hyam's criteria. We retrospectively analyzed patients with EN with Kadish stage C who were evaluated and treated at our institution between 1995 and 2009. Clinical information was collected using patient medical records, imaging, and review of pathological specimens. Twenty patients with Kadish stage C EN were identified with mean age of 51 years (31-70 years) with a median follow-up of 41.4 months (1.3-175 months). Upon pathological review, 44.4% of patients had low-grade (1/2) and 55.6% had high-grade (3/4) histology. About 37.5% of patients with low-grade EN had undergone gross total resection (GTR) and the remaining 62.5% had GTR and adjuvant radiation, whereas 50% of patients with high-grade ER had undergone GTR, 20% had undergone GTR and adjuvant radiation, and 30% had been treated with a subtotal resection (STR) and adjuvant radiation. The 5-year and 10-year survival in patients with low-grade EN was 86% in comparison to 56% and 28% with high-grade EN, respectively. In patients with low-grade EN, the 2-year progression free survival (PFS) was 86% and the 5-year PFS was 65% in comparison to 73% and 49% in patients with high-grade EN, respectively. The patient's tumor histology (Hyam's criteria) appeared to be the best way of predicting the prognosis and for selecting patients for adjuvant radiotherapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23266076      PMCID: PMC3795510          DOI: 10.1016/j.jocn.2012.05.029

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  17 in total

1.  Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.

Authors:  Daniel Jethanamest; Luc G Morris; Andrew G Sikora; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

Review 2.  Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience.

Authors:  E A McElroy; J C Buckner; J E Lewis
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

3.  Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.

Authors:  Eduardo M Diaz; Richard H Johnigan; Colin Pero; Adel K El-Naggar; Dianna B Roberts; James L Barker; Franco DeMonte
Journal:  Head Neck       Date:  2005-02       Impact factor: 3.147

4.  Esthesioneuroblastoma: irradiation alone and surgery alone are not enough.

Authors:  Günther Gruber; Kurt Laedrach; Brigitta Baumert; Marco Caversaccio; Joram Raveh; Richard Greiner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

5.  Esthesioneuroblastoma: prognosis and management.

Authors:  A Morita; M J Ebersold; K D Olsen; R L Foote; J E Lewis; L M Quast
Journal:  Neurosurgery       Date:  1993-05       Impact factor: 4.654

6.  Esthesioneuroblastoma: 25-year experience at a single institution.

Authors:  Mark E Zafereo; Samer Fakhri; Richard Prayson; Pete S Batra; Joung Lee; Donald C Lanza; Martin J Citardi
Journal:  Otolaryngol Head Neck Surg       Date:  2008-04       Impact factor: 3.497

7.  Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000.

Authors:  Jannis Constantinidis; Helmut Steinhart; Michael Koch; Michael Buchfelder; Anne Schaenzer; Manfred Weidenbecher; Heinrich Iro
Journal:  Otolaryngol Head Neck Surg       Date:  2004-05       Impact factor: 3.497

8.  Esthesioneuroblastoma: The Princess Margaret Hospital experience.

Authors:  Gideon Bachar; David P Goldstein; Manish Shah; Asheesh Tandon; Jolie Ringash; Gregory Pond; Patrick J Gullane; Bayardo Perez-Ordonez; Ralph W Gilbert; Dale H Brown; Fred Gentili; Brian O'Sullivan; Jonathan C Irish
Journal:  Head Neck       Date:  2008-12       Impact factor: 3.147

9.  Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma.

Authors:  Alyx B Porter; Dirk M Bernold; Caterina Giannini; Robert L Foote; Michael J Link; Kerry D Olsen; Timothy J Moynihan; Jan C Buckner
Journal:  J Neurooncol       Date:  2008-07-17       Impact factor: 4.130

10.  Combined modality therapy of esthesioneuroblastoma.

Authors:  J Nicolas McLean; Sunjay R Nunley; Carmen Klass; Charles Moore; Susan Müller; Peter A S Johnstone
Journal:  Otolaryngol Head Neck Surg       Date:  2007-06       Impact factor: 3.497

View more
  17 in total

Review 1.  [Neuroendocrine neoplasms of the head and neck].

Authors:  B Konukiewitz; A Agaimy; W Weichert; G Klöppel
Journal:  Pathologe       Date:  2018-02       Impact factor: 1.011

Review 2.  Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system.

Authors:  Rami E Saade; Ehab Y Hanna; Diana Bell
Journal:  Curr Oncol Rep       Date:  2015-01       Impact factor: 5.075

Review 3.  New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base.

Authors:  Lester D R Thompson; Alessandro Franchi
Journal:  Virchows Arch       Date:  2017-04-25       Impact factor: 4.064

Review 4.  Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach.

Authors:  Lester Dr Thompson
Journal:  Mod Pathol       Date:  2017-01       Impact factor: 7.842

5.  Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes.

Authors:  Diana Bell; Rami Saade; Dianna Roberts; Thomas J Ow; Michael Kupferman; Franco DeMonte; Ehab Y Hanna
Journal:  Head Neck Pathol       Date:  2014-05-08

Review 6.  Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma.

Authors:  Diana Bell
Journal:  Head Neck Pathol       Date:  2018-02-09

7.  Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013.

Authors:  Bobby A Tajudeen; Armin Arshi; Jeffrey D Suh; Miguel Fernando Palma-Diaz; Marvin Bergsneider; Elliot Abemayor; Maie St John; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-13

Review 8.  Olfactory Neuroblastoma.

Authors:  Ahmed S Abdelmeguid
Journal:  Curr Oncol Rep       Date:  2018-02-07       Impact factor: 5.075

9.  Olfactory neuroblastoma: a single-center experience.

Authors:  Marton König; Terje Osnes; Peter Jebsen; Jan Folkvard Evensen; Torstein R Meling
Journal:  Neurosurg Rev       Date:  2017-05-25       Impact factor: 3.042

Review 10.  Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis.

Authors:  Khodayar Goshtasbi; Arash Abiri; Mehdi Abouzari; Ronald Sahyouni; Beverly Y Wang; Bobby A Tajudeen; Frank P K Hsu; Gilbert Cadena; Edward C Kuan
Journal:  Int Forum Allergy Rhinol       Date:  2019-06-28       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.